DRES-05. PREDICTORS OF SENSITIVITY TO COMBINED TEMOZOLOMIDE AND PARP INHIBITOR IN GLIOMA

Agents targeting the PARP enzyme family are under active development for the treatment of gliomas. PARP inhibitors (PARPi) can enhance the effect of temozolomide (TMZ) in IDH wild-type glioblastomas, and in addition recent studies have shown that PARP inhibitors can be selectively lethal in IDH1 mut...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Nagashima, Hiroaki, Higuchi, Fumi, Lee, Christine, Rafferty, Seamus, Miller, Julie, Wakimoto, Hiroaki, Cahill, Daniel
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Drug Resistance
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847530/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.293
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares